Please login to the form below

Not currently logged in
Email:
Password:

Rixathon/Riximyo

This page shows the latest Rixathon/Riximyo news and features for those working in and with pharma, biotech and healthcare.

Sandoz joins Europe's MabThera biosimilar push

Sandoz joins Europe's MabThera biosimilar push

Sandoz will sell its biosimilar under the Rixathon/Riximyo brand names, and the firm's biopharma head, Carol Lynch, said the approval is "a big win for patients in Europe with ... There is no word on pricing for Rixathon just yet, but biosimilars

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics